山東新華製藥股份(00719.HK)再次被認定為高新技術企業
格隆匯 4 月 12日丨山東新華製藥股份(00719.HK)發佈公吿,近日,公司及其全資子公司山東淄博新達製藥有限公司(“新達製藥”)收到山東省科學技術廳、山東省財政廳、國家税務總局山東省税務局頒發的《高新技術企業證書》,證書編號分別為GR202037002800(新華製藥)、GR202037003952(新達製藥)。根據山東省科學技術廳、山東省財政廳、國家税務總局山東省税務局魯科字〔2021〕10號文件的批覆,公司及新達製藥分別再次被認定為高新技術企業,有效期3年。
公司及新達製藥法定所得税税率為25%。根據相關規定,企業獲得高新技術企業認定資格有效期內,所得税按15%的税率徵收。公司及新達製藥再次被認定為高新技術企業,自2020年(含2020年)始三年內,將繼續執行15%的所得税税率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.